Multiple Myeloma Clinical Trials in Nashville, Tennessee

24 studies are recruiting for multiple myeloma in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Tennessee Oncology, Nashville, Tennessee

   Locations

   52 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06297226 on ClinicalTrials.gov

2. A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

   This is a Phase II, open-label, nonrandomized, single-arm study of elranatamab that will be administered in the outpatient setting in 2 sequential cohorts of participants with relapsed or refractory multiple myeloma (RRMM). The primary objective of this study is to evaluate the overall incidence of…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   6 in total

   Run by

   SCRI Development Innovations, LLC

   See if you can join NCT07637578 on ClinicalTrials.gov

3. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

4. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

   The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   50 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05201781 on ClinicalTrials.gov

5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry-Joyce Cancer Clinic, Nashville, Tennessee

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

6. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   144 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

7. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refr…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Tennessee Oncology, PLLC, Nashville, Tennessee

   Locations

   71 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07266441 on ClinicalTrials.gov

8. A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

   This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment. The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) with other cancer med…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   GSK Investigational Site, Nashville, Tennessee

   Locations

   59 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT07227311 on ClinicalTrials.gov

9. MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

   The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments befo…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ascension St. Thomas Hospital, Nashville, Tennessee

   Locations

   270 in total

   Run by

   Pfizer

   See if you can join NCT06152575 on ClinicalTrials.gov

10. A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

    The study consists of three parts: * Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). *…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    GSK Investigational Site, Nashville, Tennessee

    Locations

    44 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT05714839 on ClinicalTrials.gov

11. Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

    This phase II trial tests daratumumab given at a reduced frequency with lenalidomide for maintenance therapy for the cost effective treatment of patients with multiple myeloma post stem cell transplant. Darzalex Faspor (also known as Daratumumab-hyaluronidase) is a combination of two drugs used alo…

    Stage

    Phase 2

    Ages

    18 to 70

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Eden Biltibo

    See if you can join NCT07485647 on ClinicalTrials.gov

12. A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

    A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Tennessee Oncology, Nashville, Tennessee

    Locations

    26 in total

    Run by

    K36 Therapeutics, Inc.

    See if you can join NCT05651932 on ClinicalTrials.gov

13. A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Tennessee Oncology, Nashville, Tennessee

    Locations

    21 in total

    Run by

    C4 Therapeutics, Inc.

    See if you can join NCT07284758 on ClinicalTrials.gov

14. A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

    The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Tennessee Oncology, Nashville, Tennessee

    Locations

    19 in total

    Run by

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT06121843 on ClinicalTrials.gov

15. Selinexor and Backbone Treatments of Multiple Myeloma Patients

    This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to b…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon- Tennessee Oncology Nashville, Nashville, Tennessee

    Locations

    25 in total

    Run by

    Karyopharm Therapeutics Inc

    See if you can join NCT02343042 on ClinicalTrials.gov

16. A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt Ingram Cancer Center /ID# 252470, Nashville, Tennessee

    Locations

    46 in total

    Run by

    AbbVie

    See if you can join NCT05650632 on ClinicalTrials.gov

17. A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

    This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Nashville, Tennessee

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07073547 on ClinicalTrials.gov

18. A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    SCRI Oncology Partners /ID# 278353, Nashville, Tennessee

    Locations

    49 in total

    Run by

    AbbVie

    See if you can join NCT07095452 on ClinicalTrials.gov

19. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

    This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Vanderbilt-Ingram Cancer Center (VICC), Nashville, Tennessee

    Locations

    212 in total

    Run by

    European Myeloma Network B.V.

    See if you can join NCT05243797 on ClinicalTrials.gov

20. Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

    This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patien…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Vanderbilt University, Nashville, Tennessee

    Locations

    10 in total

    Run by

    University of Alabama at Birmingham

    See if you can join NCT05231629 on ClinicalTrials.gov

21. Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

    This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

    Stage

    Phase 2

    Ages

    18 and older

    Site

    TriStar Bone Marrow Transplant, Nashville, Tennessee

    Locations

    17 in total

    Run by

    SCRI Development Innovations, LLC

    See if you can join NCT05972135 on ClinicalTrials.gov

22. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    TriStar Centennial Medical Center, Nashville, Tennessee

    Locations

    104 in total

    Run by

    Sumitomo Pharma America, Inc.

    See if you can join NCT04988555 on ClinicalTrials.gov

23. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

    Stage

    Not phased

    Ages

    40 and older

    Site

    Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

    Locations

    17 in total

    Run by

    Adela, Inc

    See if you can join NCT05366881 on ClinicalTrials.gov

24. IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

    This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and pr…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    12 in total

    Run by

    Indapta Therapeutics, INC.

    See if you can join NCT06119685 on ClinicalTrials.gov